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Editorial
SWEET – where are we heading
with international type 1 diabetes registries?
In light of the technological advances in diabetes
therapy becoming more widely available and
with healthcare costs rising generally, economic
data regarding health care are desperately needed
to allocate resources appropriately. ‘SWEET’ is
an acronym derived from ‘Better control in
Pediatric and Adolescent diabeteS: Working to
crEate CEnTers of Reference’ and is based on a
partnership of established national and European
diabetes organizations (www.sweet-project.eu) led
by the International Society for Pediatric and
Adolescent Diabetes (ISPAD), with the initial
participating pediatric centres being from the Czech
Republic, France, Germany, Greece, Hungary, Italy,
Luxembourg, the Netherlands, Poland, Portugal,
Romania, Sweden, and the UK. In addition, the
valuable contributions of the International Diabetes
Federation (IDF) Europe, the Federation of European
Nurses in Diabetes (FEND), and Primary Care
Diabetes Europe (PCDE) need to be acknowledged.
Co-funding for the initial project was granted
by the European Public Health Executive Agency
with additional funds from corporate partners and
foundations (see acknowledgements for the complete
list). The present Special Issue of Pediatric Diabetes
summarizes the major findings of the project. Before
SWEET, 17 out of 26 EU countries had officially
recognized centers for pediatric diabetes, but only eight
of them had defined criteria for becoming such a center.
A system of quality control of pediatric diabetes at the
national level was reported from 7/26 countries. Only
13/26 EU countries had a pediatric diabetes register.
These SWEET results were based on 108 datasets from
healthcare professionals caring for >29 000 children
and adolescents with diabetes in Europe.
Recommendations for diabetes care and treatment,
as well as age-appropriate education for children
and adolescents with diabetes and pediatric training
programs for healthcare professionals have been
developed by SWEET. The proposed Criteria for an
European Pediatric Diabetes Reference Centre include
a multidisciplinary approach, an ongoing electronic
documentation of at least 150 pediatric diabetes
patients ≤18 years (i.e., at least age, diabetes duration,
gender, HbA1c, type of diabetes), and the readiness to
participate in external peer-reviewed auditing process
and quality control circles.
An initial 12 centres were approved jointly by the
ISPAD Executive Committee and IDF Europe. It has
been our experience that this approval has helped
to raise awareness for the efforts to achieve optimal
diabetes care within the different local circumstances.
There is reason to believe that the international
comparison within the SWEET project will help to
secure funding from payers to ensure quality delivery
of care and to harmonize pediatric diabetes healthcare
delivery on the highest achievable standard within
the ramifications of the differing national health
systems. Optimal functioning of a team requires
clear identification of all team players, with the
child and the family at the centre of care. So far,
huge differences have been identified between the
different multidisciplinary teams, not only in numbers
of healthcare professionals, but as well their training
and the services provided. Therefore, a Toolbox
supporting the creation of Centres of Reference for
pediatric and adolescent diabetes has been developed.
For benchmarking and quality control, a platform was
put in place that allows any participating centre to
import and input data online using a standard diabetes
data set for pediatric diabetes patients to monitor
the long-term outcome after the conclusion of the
initial SWEET project. This will allow adapting the
current recommendations on the basis of the ongoing
evaluations.
Adolescents with type 1 and type 2 diabetes are
particularly prone to poor metabolic and psychosocial
outcomes due to the potentially long diabetes duration.
At the same time, the study of the effect of diabetes in
this age group provides an opportunity to study early
vascular ageing without other concomitant diseases.
Normal ageing with diabetes starts in childhood as
many processes leading to debilitating complications
later in life have their onset then. This offers a
unique opportunity to identify potential factors that
are important to delay accelerated biological ageing
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in diabetes. Also, preventive strategies that prove
effective in childhood and adolescence are likely to
be particularly cost-effective as most of the healthcare
cost is incurred for the treatment of late complications.
Despite guidelines and consensus statements related
to approaches, targets and therapies, there remains
huge variation across EU Member States in the
quantity and quality of diabetes-related clinical
research and in care available for people with
diabetes. This variability in research activity and service
delivery is a consequence of many factors, the most
significant being the social and cultural differences
among countries, differences in clinical governance,
and lack of structured networks of interested parties
with commonly agreed goals.
Cross-sectional international analyses have repeat-
edly shown that the outcomes of pediatric diabetes care
show considerable differences between centers that are
not easily explained (1). But there is reason for an opti-
mistic outlook. Longitudinal analyses over the years
in Germany and Austria included data from 30 708
patients documented in 305 diabetes centers between
1995 and 2009 (2). After multiple adjustments, mean
HbA1c within this network decreased significantly by
0.038% per year. The Swedish registry also includes
longitudinal data for >10 years (3). Although there
may be a multitude of reasons for this improvement
in the outcomes of pediatric diabetes, the longitu-
dinal rather than cross-sectional electronic follow-up
appears to be an important tool for local, national as
well as international benchmarking and quality con-
trol circles. Thus, similar initiatives have been started
elsewhere. In Kuwait, the SWEET survey was used
to assess the structure of diabetes education (4). In
the USA, the T1D Exchange was founded in 2010
through a grant from The Leona M. and Harry B.
Helmsley Charitable Trust’s Type 1 Diabetes Program
(www.t1dexchange.org). Individuals are being enrolled
into the Registry at 67 centers throughout the USA.
The current issue of Pediatric Diabetes summa-
rizes the outcomes of the SWEET project, and
the complete SWEET reports can be found online
at http://www.sweet-project.eu/index.php/country-
reports/sweet-reports.
This web page also contains an email-link for
reporting amendments, updates and corrections. An
on-line comparison tool located at http://www.sweet-
project.eu/index.php/country-reports enables one to
compare parameters of any two countries. Finally,
a toolbox supporting the creation of Centres of
Reference for pediatric and adolescent diabetes will
be put in place.
The basis for the future development of SWEET
will be the electronic health record. Two electronic
databases have been developed within the SWEET
project for those centers not having an electronic health
record of their own. The basic system DIAMAX:mini
is available for free download for all ISPAD members
for data collection purposes. It has been developed
for all diabetes specialists who do not yet use an
electronic health record and want to start electronic
documentation on a limited scale. An easy export
function from DIAMAX:mini into EXCEL will allow
individual scientific analyses. As an ISPAD member,
you receive the software free of charge by clicking on
the submit button which will forward you to get your
free download. You will find DIAMAX:mini on the
page you first get to when logging in. If you are already
logged in, go to ‘Members’ ‘My Page’. It is possible to
upgrade DIAMAX:mini to the professional diabetes-
outpatient-system [DPV2] DIAMAX at any time.
Compared to DIAMAX:mini several extra features
are implemented in [DPV2] DIAMAX exclusively,
(e.g., detailed doctor’s letters, individual therapy
plans, informative patient quick overviews, enhanced
statistics, flexible charts, significant patient summaries,
etc.). Aggregate data is de-identified and can be
exported to the SWEET project from this and various
other databases with SWEETconv conversion tool for
longitudinal data analysis. Eventually patients will
also have the ability to logon to their own secure
portal to complete outcomes assessments, receive
relevant reminders and education material, as well
as communicate with their local pediatric diabetes
treatment center. In a first step, the SWEET Online
platform will allow 12 countries in several languages to
connect to one unified diabetes database.
The European DIAMAP project (5) proposed a
European Platform for Clinical Research in Diabetes
(EPCRD) to address these issues as well as other
more generic obstacles toward clinical research for the
benefit of individuals with diabetes Europe. A large
population of people with diabetes with variations
in genetic and ethnic background could be made
accessible to clinical (and basic) researchers and the
sponsors of research by participation in a network with
a centralized point of entry. The DIAMAP road maps
have repeatedly mentioned as roadblocks the need for
registries of patients, networks of specialist researchers,
access to biobanks and human biological material
(especially in relation to the rarer complications) and
the need for more standardized treatment guidelines
(Fig. 1). It was felt strongly that diabetes research
would be enhanced if the clinical research community
itself could drive a collaborative initiative as it deals
with the consequences of research upon treatment
and care delivery. Clinical research, from small
studies to large-scale pharmaceutical trials, or research
into health service provision is more laborious and
less representative than it could be because of the
number of countries, languages and organizational
cultures.
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Fig. 1. DIAMAP: the pediatric roadmap for diabetes research (www.diamap.eu). Modified figure from Chapter 4. John J. Nolan (Chair),
Thomas Danne, Michaela Diamant, Gillian Hood, Alexandra Kautzky-Willer, David Kerr, Asmina Mitrakou, Peter M. Nilsson, Giovanni
Pacini. Clinical science and care incorporating the development of a European platform for clinical research in diabetes. The need for
networking and data bases as basis for enhancing Pediatric Diabetes Research.
We believe that a collaboration of these national and
international initiatives will allow a joint evaluation
of these invaluable data sets. It could improve the
situation for children with diabetes in Europe and
beyond ensuring that all children have the right to
participate fully in all the experiences of childhood and
adolescence, regardless of whether they have diabetes
and wherever they live. Also it could reduce the effects
of accelerated vascular ageing imposed by the diabetic
state and provide the basis for a long-term participa-
tion in professional and family life without or with
delayed debilitating long-term diabetes complications.
Under the umbrella of our scientific society ISPAD,
the goal of the newly created legal entity SWEET is
to continuously develop these recommendations for
structure, process and outcome quality with regard
to the treatment strategies and standards for pediatric
diabetology, on the basis of longitudinal international
patient data, as well as creating training programs
for diabetes experts and patients. The SWEET project
hopes to extend from the initial group of centres
within countries and throughout Europe and beyond
with the help of the ISPAD network.
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